Three to four mRNA COVID‐19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization
European Journal of Neurology · 2023
DOI: 10.1111/ene.15925 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Céline Louapre und 13 weiteren Autor:innen. Beteiligte Einrichtung: CIC Neurosciences, Hôpital de la Pitié Salpêtrière, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris Brain Institute-I…. Hauptthemen laut MEDLINE: Multiple Sclerosis, COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and purpose An enhanced severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine regimen could improve humoral vaccine response in patients with multiple sclerosis (MS) treated by anti‐CD20. The aim was to evaluate the serological response and the neutralizing activity after BNT162b2 primary and booster vaccination in MS patients, including patients on anti‐CD20 receiving a primary vaccine regimen enhanced with three injections.
Methods
In this prospective longitudinal cohort study of 90 patients (47 on anti‐CD20, 10 on fingolimod, 33 on natalizumab, dimethylfumarate or teriflunomide), anti‐SARS‐CoV‐2 receptor binding domain (RBD) immunoglobulin G antibodies were quantified and their neutralization capacity was evaluated by enzyme‐linked immunosorbent assay (GenScript) and a virus neutralization test against B.1 historical strain, Delta and Omicron variants, before and after three to four BNT162b2 injections.
Results
After the primary vaccination scheme, the anti‐RBD positivity rate was strongly decreased in patients on anti‐CD20 (28% [15%; 44%] after two shots, 45% [29%; 62%] after three shots) and fingolimod (50% [16%; 84%]) compared to other treatments (100% [90%; 100%]). Neutralization activity was also decreased in patients on anti‐CD20 and fingolimod, and notably low for the Omicron variant in all patients (0%–22%). Delayed booster vaccination was performed in 54 patients, leading to a mild increase of anti‐RBD seropositivity in patients on anti‐CD20 although it was still lower compared to other treatments (65% [43%; 84%] vs. 100% [87%; 100%] respectively). After a booster, Omicron neutralization activity remained low on anti‐CD20 and fingolimod treated patients but was strongly increased in patients on other treatments (91% [72%; 99%]).
Discussion
In MS patients on anti‐CD20, an enhanced primary vaccination scheme moderately increased anti‐RBD seropositivity and anti‐RBD antibody titre, but neutralization activity remained modest even after a fourth booster injection. Trial registration information COVIVAC‐ID, NCT04844489 , first patient included on 20 April 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CIC Neurosciences, Hôpital de la Pitié Salpêtrière, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris Brain Institute-ICM, Paris, France.
- Département de Santé Publique, Groupe Hospitalier Universitaire APHP-Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Site Pitié-Salpêtrière, Sorbonne Université, Paris, France.
- Laboratoire de Virologie, Assistance Publique Hôpitaux de Paris, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Sorbonne Université, Paris, Fr…
- Reqpharm Unit, Pharmacie à Usage Intérieur, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France.
- INSERM Inflammation-Immunopathology-Immunotherapy Department (i3) and AP-HP, Hôpital Pitié-Salpêtrière, Clinical Investigation Center for Biotherapies (CIC-BTi), Sorbonne Université, Paris, France.
- Service de Maladies infectieuses et Tropicales, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Sorbonne Université, Paris, France.
ORCID-Profile: Céline Louapre, Edouard Januel, Lina Jeantin, Valérie Pourcher
Zitieren
APA
Louapre, C., Belin, L., Marot, S., Hippolyte, A., Januel, E., Ibrahim, M., Jeantin, L., Zafilaza, K., Malet, I., Charbonnier-Beaupel, F., Rosenzwajg, M., Soulié, C., Marcelin, A. G., & Pourcher, V. (2023). Three to four mRNA COVID‐19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization. European Journal of Neurology. https://doi.org/10.1111/ene.15925
Vancouver
Louapre C, Belin L, Marot S, Hippolyte A, Januel E, Ibrahim M, et al. Three to four mRNA COVID‐19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization. European Journal of Neurology. 2023. doi:10.1111/ene.15925
BibTeX
@article{Louapre2023,
author = {Louapre, Céline and Belin, Lisa and Marot, Stéphane and Hippolyte, Amandine and Januel, Edouard and Ibrahim, Michella and Jeantin, Lina and Zafilaza, Karen and Malet, Isabelle and Charbonnier-Beaupel, Fanny and Rosenzwajg, Michelle and Soulié, Cathia and Marcelin, Anne-Geneviève and Pourcher, Valérie},
title = {Three to four mRNA COVID‐19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization},
journal = {European Journal of Neurology},
year = {2023},
doi = {10.1111/ene.15925}
}
EUVIMED